drugset / Trial / NCT00107523

Pravastatin, Idarubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT00107523

Phase 1 Completed Fred Hutchinson Cancer Center
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin may help idarubicin and cytarabine work better by making cancer cells more sensitive to the drugs. Giving pravastatin together with idarubicin and cytarabine may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of pravastatin when given together with idarubicin and cytarabine in treating patients with acute myeloid leukemia.

Timeline

Start
2005-01
Primary completion
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pravastatin Small molecule Oral
Background Cytarabine Small molecule Intravenous
Background Idarubicin Small molecule Intravenous

Indications